ArticleCirculation2025
Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart.
Article in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pirfenidone Suppresses Liver Fibrosis Through Inhibition of TGF-β-Associated Lipid Metabolic Remodeling in Hepatic Stellate Cells.International journal of molecular sciences · 2026Article
- Cardiac fibroblast heterogeneity in cardiac fibrosis implication for cell-type-specific treatment.Frontiers in physiology · 2026Review
- Macrophage ITGAV is dispensable for post-infarction remodeling in mice and does not mediate fibronectin responses.Communications biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn patients surviving myocardial infarction, adipose tissue infiltration within the scar is a common pathological finding and has been suggested to contribute to dysfunction and arrhythmogenesis. However, the cellular mechanisms for lipomatous metaplasia after infarction remain enigmatic. Our study reveals a novel molecular mechanism that mediates fibroblast-to-adipocyte conversion and causes fatty infiltration in the infarcted heart.
methodsMice with fibroblast-specific disruption of TGF-β (transforming growth factor-β) or Smad-dependent signaling and corresponding controls were generated and underwent reperfusion and nonreperfusion myocardial infarction protocols. Echocardiography, histological studies, and transcriptomic analysis were used to study effects on cardiac repair and remodeling. Lineage tracing experiments were used to document fibroblast-to-adipocyte conversion. In vitro, the effects of genetic disruption or pharmacological blockade of TGF-β signaling on mouse cardiac fibroblasts were examined. Single-cell RNA sequencing data from human patients with myocardial infarction were analyzed to assess fibroblast-to-adipocyte conversion.
resultsFibroblast-specific abrogation of TGF-β signaling through deletion of TbR2 (type 2 TGF-β receptor) increased the incidence of early postinfarction cardiac rupture, promoting a matrix-degrading fibroblast phenotype. Moreover, fibroblast-specific TbR2 loss resulted in replacement of 30% to 40% of the mature scar with adipocytes in both reperfused and nonreperfused infarcts. Lineage tracing demonstrated that fibroblast-specific TbR2 loss promotes fibroblast-to-adipocyte conversion through effects that involve Smad-independent cascades. In vitro, TbR2 inhibition induced expression of adipogenesis-associated genes in primary cardiac fibroblasts. Genetic TbR2 loss promoted conversion of infarct fibroblasts to adipocytes upon stimulation with adipogenic medium. A subpopulation of fibroblasts in human fibrotic infarcted hearts acquired expression of adipocyte genes.
conclusionsTGF-β signaling plays a central role in maintaining fibroblast cell specification after cardiac injury. Fibroblast-to-adipocyte conversion induced by disrupted TGF-β signaling may underlie scar-associated lipomatous metaplasia and may play an important role in the pathogenesis of heart failure and arrhythmogenesis in patients with ischemic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.